MedTrace Logo

Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification

NCT01657266 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2018-10-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution PRO-155 in patients post phacoemulsification.

Conditions

  • Cataract
  • Phacoemulsification Cataract Surgery

Interventions

DRUG

PRO-155

Pre-medication (before surgery) and maintenance treatment.

DRUG

Nevanac

Pre-medication (before surgery) and maintenance treatment.

Sponsors & Collaborators

  • Laboratorios Sophia S.A de C.V.

    lead INDUSTRY

Principal Investigators

  • Leopoldo M. Baiza-Durán, MD · Laboratorios Sophia S.A de C.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-03-31
Completion
2015-04-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01657266 on ClinicalTrials.gov